• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国肺癌患者早期死亡的风险因素:一项全国性分析。

Risk factors for early mortality of lung cancer patients in France: A nationwide analysis.

机构信息

Département de Pneumologie, CHI de Créteil, Créteil, France.

Centre de Recherche Clinique, CHI de Créteil, Créteil, France.

出版信息

Cancer Med. 2022 Dec;11(24):5025-5034. doi: 10.1002/cam4.4821. Epub 2022 May 14.

DOI:10.1002/cam4.4821
PMID:35567378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9761075/
Abstract

BACKGROUND

Despite therapeutic advances, lung cancer remains the first cause of death from cancer. The main objective of this study was to identify risk factors associated with death within 3-months of the first hospitalization for lung cancer in France.

METHODS

This analysis included patients with a first hospitalization for lung cancer (between January 1, 2016 and December 31, 2018) according to diagnosis-related groups entered into the French national medical-administrative database. Clinical and socioeconomic parameters and characteristics of that first hospitalization were analyzed. A model predictive of early mortality was developed based on those variables.

RESULTS

The 144,087 included patients were 67% men; median age of 68 [interquartile range 60-76] years; 47% had metastatic disease at diagnosis; and 34% and 23%, respectively, had received systemic treatment or undergone curative surgery. The 3-month mortality was 19%, and significantly higher for those ≥70 versus <70 years old (OR 1.33, 1.22-1.45), men versus. women (OR 1.50, 1.44-1.55), those with metastatic disease at diagnosis (OR, 3.30, 3.18-3.43), first hospitalization via the emergency room (OR 1.65 1.59-1.71) and first hospitalization lasting >30 days (OR, 1.58 1.49-1.68). In contrast, no socioeconomic characteristic was associated with early mortality.

CONCLUSION

Almost 1 in 5 patients diagnosed with lung cancer in France died within 3 months post-diagnosis. Improving survival requires diagnosis at an earlier stage and better organization of diagnosis and specific care pathways.

摘要

背景

尽管治疗取得了进展,但肺癌仍是癌症死亡的首要原因。本研究的主要目的是确定与法国首次因肺癌住院后 3 个月内死亡相关的风险因素。

方法

本分析纳入了 2016 年 1 月 1 日至 2018 年 12 月 31 日期间根据诊断相关组进入法国国家医疗管理数据库的首次因肺癌住院的患者。分析了临床和社会经济参数以及首次住院的特征。根据这些变量开发了一个预测早期死亡率的模型。

结果

纳入的 144087 名患者中,67%为男性;中位年龄为 68[60-76]岁;47%在诊断时患有转移性疾病;分别有 34%和 23%接受了系统治疗或进行了根治性手术。3 个月死亡率为 19%,年龄≥70 岁与<70 岁相比显著更高(OR 1.33,1.22-1.45),男性与女性相比(OR 1.50,1.44-1.55),诊断时患有转移性疾病(OR 3.30,3.18-3.43),通过急诊室入院(OR 1.65,1.59-1.71)和首次住院时间>30 天(OR,1.58,1.49-1.68)。相比之下,没有社会经济特征与早期死亡率相关。

结论

在法国诊断出的肺癌患者中,近 1/5 在诊断后 3 个月内死亡。提高生存率需要更早地诊断,以及更好地组织诊断和特定的护理途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095f/9761075/bfd96c45d234/CAM4-11-5025-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095f/9761075/bfd96c45d234/CAM4-11-5025-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095f/9761075/bfd96c45d234/CAM4-11-5025-g001.jpg

相似文献

1
Risk factors for early mortality of lung cancer patients in France: A nationwide analysis.法国肺癌患者早期死亡的风险因素:一项全国性分析。
Cancer Med. 2022 Dec;11(24):5025-5034. doi: 10.1002/cam4.4821. Epub 2022 May 14.
2
In-hospital mortality following lung cancer resection: nationwide administrative database.肺癌切除术后院内死亡率:全国性行政数据库。
Eur Respir J. 2016 Jun;47(6):1809-17. doi: 10.1183/13993003.00052-2016. Epub 2016 Mar 10.
3
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.法国全国性队列研究:转移性肺癌治疗中创新药物的可及性:TERRITOIRE 研究。
BMC Cancer. 2018 Oct 22;18(1):1013. doi: 10.1186/s12885-018-4958-5.
4
Epidemiology of trauma in France: mortality and risk factors based on a national medico-administrative database.法国创伤流行病学:基于国家医学管理数据库的死亡率和危险因素。
Anaesth Crit Care Pain Med. 2019 Oct;38(5):461-468. doi: 10.1016/j.accpm.2019.02.007. Epub 2019 Feb 23.
5
Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.肺癌早期死亡的风险因素:法国全国 KBP 队列研究过去 20 年的演变。
ESMO Open. 2024 Jun;9(6):103594. doi: 10.1016/j.esmoop.2024.103594. Epub 2024 Jun 7.
6
Early mortality in lung cancer: French prospective multicentre observational study.肺癌的早期死亡率:法国前瞻性多中心观察性研究。
BMC Pulm Med. 2016 Apr 2;16:45. doi: 10.1186/s12890-016-0205-5.
7
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).法国进行性纤维性间质性肺病的流行病学、死亡率和疾病负担评估(PROGRESS 研究)。
Respir Res. 2021 May 24;22(1):162. doi: 10.1186/s12931-021-01749-1.
8
National Trends in Patients Hospitalized for Stroke and Stroke Mortality in France, 2008 to 2014.2008年至2014年法国中风住院患者及中风死亡率的全国趋势
Stroke. 2017 Nov;48(11):2939-2945. doi: 10.1161/STROKEAHA.117.017640. Epub 2017 Sep 29.
9
Timing in initiating lung cancer treatment after bronchoscopy in France: Study from medico-administrative database.法国支气管镜检查后启动肺癌治疗的时机:基于医疗行政数据库的研究
Lung Cancer. 2016 May;95:44-50. doi: 10.1016/j.lungcan.2016.02.016. Epub 2016 Mar 2.
10
The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart.男性非小细胞肺癌的新面貌:两项间隔10年开展的法国前瞻性流行病学研究结果
Lung Cancer. 2016 Jan;91:1-6. doi: 10.1016/j.lungcan.2015.11.001. Epub 2015 Nov 15.

引用本文的文献

1
Thromboinflammatory Biomarkers Are Early Predictors of Disease Progression in Non-Small Cell Lung Cancer Patients.血栓炎症生物标志物是非小细胞肺癌患者疾病进展的早期预测指标。
Cancers (Basel). 2025 Jun 10;17(12):1932. doi: 10.3390/cancers17121932.
2
Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.肺癌早期死亡的风险因素:法国全国 KBP 队列研究过去 20 年的演变。
ESMO Open. 2024 Jun;9(6):103594. doi: 10.1016/j.esmoop.2024.103594. Epub 2024 Jun 7.
3
Lung cancer in the emergency department.

本文引用的文献

1
The Effect of Advances in Lung-Cancer Treatment on Population Mortality.肺癌治疗进展对人群死亡率的影响。
N Engl J Med. 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623.
2
Gender and lung cancer-SEER-based analysis.性别与肺癌——基于 SEER 的分析。
Ann Epidemiol. 2020 Jun;46:14-19. doi: 10.1016/j.annepidem.2020.04.003. Epub 2020 May 7.
3
Early mortality of stage IV non-small cell lung cancer in the United States.美国 IV 期非小细胞肺癌的早期死亡率。
急诊科中的肺癌
Emerg Cancer Care. 2023;2(1):3. doi: 10.1186/s44201-023-00018-9. Epub 2023 Mar 6.
Acta Oncol. 2019 Aug;58(8):1095-1101. doi: 10.1080/0284186X.2019.1599138. Epub 2019 Apr 8.
4
Socioeconomic Differences and Lung Cancer Survival-Systematic Review and Meta-Analysis.社会经济差异与肺癌生存率——系统评价与荟萃分析
Front Oncol. 2018 Nov 27;8:536. doi: 10.3389/fonc.2018.00536. eCollection 2018.
5
Prediction of early mortality following stereotactic body radiotherapy for peripheral early-stage lung cancer.立体定向体部放疗治疗周围型早期肺癌患者的早期死亡预测。
Acta Oncol. 2019 Feb;58(2):237-242. doi: 10.1080/0284186X.2018.1532602. Epub 2018 Nov 19.
6
Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer.辅助化疗治疗非小细胞肺癌患者的早期死亡率。
J Thorac Oncol. 2018 Apr;13(4):543-549. doi: 10.1016/j.jtho.2018.01.010. Epub 2018 Feb 2.
7
A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.根治性放化疗后非小细胞肺癌患者早期死亡预测模型。
Acta Oncol. 2018 Feb;57(2):226-230. doi: 10.1080/0284186X.2017.1385842. Epub 2017 Oct 14.
8
Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).法国肺癌患者的生存不平等:一项全国性队列研究(TERRITOIRE研究)
PLoS One. 2017 Aug 25;12(8):e0182798. doi: 10.1371/journal.pone.0182798. eCollection 2017.
9
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.法国的国家医疗保健系统拥有SNIIRAM和EGB数据库:药物流行病学的强大工具。
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962. doi: 10.1002/pds.4233. Epub 2017 May 24.
10
Prediction of Early Death in Patients with Early-Stage NSCLC-Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach?早期非小细胞肺癌患者的早期死亡预测——我们能否选择没有立体定向放疗潜在获益的患者作为一种根治性治疗方法?
J Thorac Oncol. 2016 Jul;11(7):1132-9. doi: 10.1016/j.jtho.2016.03.016. Epub 2016 Apr 7.